Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 706 plus paclitaxel versus placebo plus paclitaxel, with an open-label bevacizumab plus paclitaxel reference arm, in first-line HER2-negative recurrent or metastatic breast cancer
2006-000091-32Phase 2Terminated
- Sponsor
- Amgen
- Start
- Mar 2006
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Paclitaxel + AMG 706 placebo, Paclitaxel + AMG 706 and Paclitaxel + bevacizumab (3 arms). Primary endpoint: Objective response rate. Started Mar 2006; status: terminated.
02
Drugs
motesanibpaclitaxelbevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-000091-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000091-32.